fda removing semaglutide Novo asks to bar compounders from making copies fda shortage list semaglutide The

In Phase 2 trials, participants achieved an average weight loss of 24.2% of their body weight over 48 weeks

doi:10.1016/j.biopha.2021.111286 55

Administered via a subcutaneous injection once a week, the treatment aligns effectively with personalized plans

As of 2022, GLP-1RAs have been recommended as first-line treatments, along with SGLT-2 inhibitors, for patients with T2DM and cardiovascular disease in American Diabetes Associations Standards of Medical Care in Diabetes (248, 249)

It won't have the same degree of weight loss from what we can see in the early trials, she advises, but it will help retain lean muscle mass, which we inevitably lose over our lifetime. Given that semaglutide is a lifelong drug, the long-term data on GLP-1 agonists is reassuringly positive